Loading
A phase 3 trial of Bempegaldesleukin and Nivolumab in Melanoma, run by Nektar Therapeutics, recorded as terminated on the registry.
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence is a phase 3 interventional study registered as NCT04410445 by Nektar Therapeutics, with 765 participants recorded, started 2020-07-27 and due to reach its primary completion in 2022-09-22. Interventions recorded: Bempegaldesleukin, Nivolumab. Conditions recorded: Melanoma, Melanoma Stage III, Melanoma Stage IV, Melanoma (Skin).
Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.
Shares Nektar Therapeutics, Bempegaldesleukin, Nivolumab and the tag pipeline.
Shares Bempegaldesleukin, Nivolumab, Melanoma and the tag pipeline.
Shares Nivolumab and the tag pipeline.
Shares Melanoma and the tag pipeline.
Shares Nivolumab and the tag pipeline.
Shares Nivolumab and the tag pipeline.
Shares Melanoma and the tag pipeline.